Trial design: 751 adults with obesity (BMI 30, or 27 with at least one comorbidity) No type 2 diabetes 72-week follow-up Tirzepatide 10mg or 15mg vs Semaglutide 2.4mg Results at 72 weeks: When looking at tirzepatide weight loss results from SURMOUNT-5 alongside semaglutide weight loss results from the STEP trials, the gap is consistent and statistically significant across every subgroup sex, age, baseline BMI, and presence of metabolic comorbidities
These groundbreaking medications, initially approved for patients with type 2 diabetes, are now revolutionizing chronic disease treatment through their metabolic, hormonal, and anti-inflammatory effects, becoming vital tools in addressing conditions like cardiovascular disease, non-alcoholic fatty liver disease, osteoarthritis, and more.
After approval, they need to ramp up to commercial scale, producing millions of doses per month instead of thousands
With InjectCos tirzepatide weight loss program in The Woodlands, you can lose excess fat under physician supervision while rebuilding confidence in how your body looks and feels
